AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05613036
Drug: BI 907828
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 907828
Trial: NCT06161974
Drug: Olutasidenib + TMZ
RxNorm normalized name: Olutasidenib
DrugBank: Olutasidenib (DB16267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olutasidenib 150 mg PO BID + Temozolomide 200 mg/m2 PO QD
Trial: NCT06547203
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab: 3 mg/kg, intravenous infusion, once every 2 weeks.
Trial: NCT06547203
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan: 150 mg/m², intravenous infusion, once every 2 weeks.
Trial: NCT04818151
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin treatment for VTE
Trial: NCT04818151
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban treatment for VTE
Trial: NCT05223231
Drug: anti-PD-1 antibody injection
RxNorm normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: provide medicine base on needs
Trial: NCT00021671
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00021671
Drug: Ampicillin sodium
RxNorm normalized name: Ampicillin Sodium
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00021671
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06241456
Drug: FT825
RxNorm normalized name: Fostamatinib
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: FT825 will be administered as an intravenous (IV) infusion at planned dose levels.
Trial: NCT06241456
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine will be administered as an IV infusion at planned dose levels.
Trial: NCT06241456
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine will be administered as an IV infusion at planned dose levels.
Trial: NCT06241456
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be administered as an IV infusion at planned dose levels.
Trial: NCT06241456
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin will be administered as an IV infusion at planned dose levels.
Trial: NCT06241456
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab will be administered as an IV infusion at planned dose levels.
Trial: NCT05461339
Drug: TAB014 Monoclonal Antibody Injection
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravitreal injection at 1.25mg once every 4 weeks
Trial: NCT05461339
Drug: Ranibizumab Injection [Lucentis]
RxNorm normalized name: ranibizumab Injection [Lucentis]
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravitreal injection at 0.5mg once every 4 weeks
Trial: NCT06458400
Drug: Tegileridine
RxNorm normalized name: Tegileridine
DrugBank: Tegileridine (DB18988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose+PCA dose
Trial: NCT06458400
Drug: Oliceridine
RxNorm normalized name: Oliceridine
DrugBank: Oliceridine (DB14881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose+PCA dose
Trial: NCT06458400
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose+PCA dose
Trial: NCT06530563
Drug: Oliceridine Injection [Olinvyk]
RxNorm normalized name: oliceridine Injection [Olinvyk]
DrugBank: Oliceridine (DB14881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oliceridine fumarate injection, specifications: 1mg/1mL, 2mg/2 mL, 10mg/10 mL; Stored in the dark, 15-30 ℃, not frozen; Jiangsu Nhwa pharmaceutical co., LTD. Production.
Trial: NCT05185115
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of oxygen at a flow rate of 3 liters per minute, via nasal cannula throughout the hospitalization.
Trial: NCT04966741
Drug: Setmelanotide
RxNorm normalized name: Setmelanotide
DrugBank: Setmelanotide (DB11700)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: SC injection once daily.
Trial: NCT06100289
Drug: Vedolizumab IV
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab IV injection.
Trial: NCT06100289
Drug: Vedolizumab SC
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab SC injection.
Trial: NCT05570253
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin 1.4 mg/m2 IV on days 1 and 8 of an every 21 day cycle.
Trial: NCT05570253
Drug: SDX-7320
RxNorm normalized name: METAP2 inhibitor SDX-7320
DrugBank: Evexomostat (DB19140)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDX-7320 at the dose of 49 mg/m2 SC on a Q14D basis
Trial: NCT04743505
Drug: APL-101
RxNorm normalized name: APL-502
DrugBank: APL-502 (DB17473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -Provided by Apollomics
Trial: NCT04743505
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: -Given standard of care
Trial: NCT05014828
Drug: lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Capsules administered orally
Trial: NCT05014828
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous (iv) infusion
Trial: NCT04949867
Drug: Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon is filled in the pump and given automatically in case of hypoglycemia or pending hypoglycemia.
Trial: NCT05015881
Drug: FDG
RxNorm normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Echocardiogram, and 2-Deoxy-2-\[18F\] fluoro-D-glucose (FDG) PET scan.
Trial: NCT04220203
Drug: Tucatinib
RxNorm normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg orally two times per day
Trial: NCT04220203
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loading dose of 8 mg/kg into the vein (IV; intravenously), followed by 6 mg/kg IV once per 21-day cycle
Trial: NCT05012137
Drug: different volume of 0.5% ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: According to the subject's response to the injection dose, the next subject will be injected with a different volume of the drug according to the preset rules
Trial: NCT05031481
Drug: Butoconazole nitrate
RxNorm normalized name: Butoconazole Nitrate
DrugBank: Butoconazole (DB00639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Butoconazole nitrate vaginal cream, 100 mg single-dose.
Trial: NCT00451139
Drug: artemether/lumefantrine
RxNorm normalized name: Artemether/lumefantrine
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00451139
Drug: quinine
RxNorm normalized name: Quinine
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00451139
Drug: atovaquone/proguanil
RxNorm normalized name: ATOVAQUONE/PROGUANIL
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05357547
Drug: Buspirone 20mg
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buspirone tablets in opaque capsule. Used as probe for 5HT1A agonism
Trial: NCT04968379
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous
Trial: NCT04896385
Drug: Ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Trial: NCT05129891
Drug: Semaglutide D
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet given orally
Trial: NCT06163833
Drug: Mesenchymal stromal cell low dosage-80*10^6 cells
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSCs have to be administered at the dosage of 80\*10\^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL.
Trial: NCT06163833
Drug: Mesenchymal stromal cell low dosage-160*10^6 cells
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSCs have to be administered at the dosage of 160\*10\^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL.
Trial: NCT05129891
Drug: Semaglutide G
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet given orally
Trial: NCT05129891
Drug: Semaglutide H
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet given orally
Trial: NCT05129891
Drug: Semaglutide I
RxNorm normalized name: semaglutide Injectable Product
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet given orally
Trial: NCT05129891
Drug: NNC0385-0434 C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet given orally
Trial: NCT05129891
Drug: NNC0385-0434 D
RxNorm normalized name: D
DrugBank: Rosomidnar (DB17154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet given orally
Trial: NCT05129891
Drug: NNC0385-0434 E
RxNorm normalized name: E-EPA
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet given orally
Trial: NCT05269667
Drug: Satralizumab 120 mg
RxNorm normalized name: satralizumab 120 mg/mL subcutaneous solution
DrugBank: Satralizumab (DB15762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Satralizumab 120 mg will be administered as monotherapy (SC) in the abdominal or femoral region at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Weeks 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).
Trial: NCT05799105
Drug: Omeprazole 40 milligrams
RxNorm normalized name: omeprazole 40 MG
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to treatment with either open-capsule or intact-capsule omeprazole to assess effect on ulcer healing times. If interim analysis illustrates significantly improved healing in the open-capsule group, the control (intact-capsule) arm will be allowed to cross-over to open-capsule and be followed until confirmed ulcer healing.
Trial: NCT05895136
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human albumin solution is made from pooled human plasma. It is widely used as a plasma-expander in several disease conditions, such as liver cirrhosis and critically ill patients.~ATC-Code: B05AA01
Trial: NCT04905979
Drug: AD113
RxNorm normalized name: Aducanumab
DrugBank: Aducanumab (DB12274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two oral capsules administered before bed
Trial: NCT04905979
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two oral capsules administered before bed
Trial: NCT04842422
Drug: Imiquimod 3.75% Cream
RxNorm normalized name: IMIQUIMOD 3.75% CREAM,TOP
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod 3.75% Cream
Trial: NCT06394804
Drug: Avutometinib
RxNorm normalized name: Avutometinib
DrugBank: Avutometinib (DB15254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting Dose 3.2 mg BIW for 3 of 4 weeks, Dose -1, 2.4 mg BIW for 3 of 4 weeks
Trial: NCT06394804
Drug: Defactinib
RxNorm normalized name: Defactinib
DrugBank: Defactinib (DB12282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting Dose 200 mg BID for 3 of 4 weeks, Dose -1, 200 mg QD for 3 of 4 weeks
Trial: NCT06394804
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg PO daily
Trial: NCT05476679
Drug: RZL-012+Lidacaine injection prior treatment
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5ml lidocaine will be injected 10 minutes before RZL-012 treatment
Trial: NCT05895136
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin is a drug that belongs to the group of anticoagulants. It exerts its antithrombotic activity by binding to antithrombin III (AT III). ATC-Code: B01AB05
Trial: NCT05886049
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05886049
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05886049
Drug: Revumenib
RxNorm normalized name: Revumenib
DrugBank: Revumenib (DB18515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06016933
Drug: spirulina gel
DrugBank: Spirulina platensis (DB14744)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient were received spirulina gel in diseased sites. The process will be repeated at 7, 14, 21 days.
Trial: NCT04866485
Drug: HBM4003 and pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will be treated with HBM4003 and pembrolizumab on Day 1 during each 21-day cycles.
Trial: NCT05797168
Drug: Saruparib (AZD5305)
RxNorm normalized name: Saruparib
DrugBank: Saruparib (DB18982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PARP inhibitor
Trial: NCT05797168
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV Monoclonal antibody
Trial: NCT05797168
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Alkylating agent
Trial: NCT04950127
Drug: Linerixibat
RxNorm normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive linerixibat.
Trial: NCT06434350
Drug: Enfortumab Vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV
Trial: NCT04976868
Drug: Pimecrolimus 1% Top Cream
RxNorm normalized name: PIMECROLIMUS 1% TOP CREAM
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elidel® as prescribed within routine clinical practice
Trial: NCT04733144
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1,125 mg dexamethasone 4,5 mg dexamethasone
Trial: NCT05797506
Drug: Sulforaphane (Avmacol Extra Strength)
RxNorm normalized name: Sulforaphane
DrugBank: Sulforaphane (DB12422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 Tablets of Sulforaphane (Avmacol Extra Strength) per day in patients with Chronic Kidney Disease, stages 3-4.
Trial: NCT06008795
Drug: Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone
RxNorm normalized name: Ivy Block
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each PPF-active nerve block will consist of 20mg (4ml) ropivacaine plus 4mg (1ml) dexamethasone
Trial: NCT04948697
Drug: Ociperlimab
RxNorm normalized name: Ociperlimab
DrugBank: Ociperlimab (DB18947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg intravenously once every 3 weeks (dosed in 21-day cycles)
Trial: NCT04948697
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg intravenously once every 3 weeks (dosed in 21-day cycles)
Trial: NCT05615974
Drug: LM101
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05615974
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05615974
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously
Trial: NCT04898114
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulized magnesium sulfate (4 ml of 6.4% solution) every 15 minutes
Trial: NCT04898114
Drug: Sildenafil Citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sildenafil citrate at an initial dose of 1 mg/kg, with incremental increases by 0.5 mg/kg every 6 hours till reaching a target dose of 2mg/kg every 6 hours.
Trial: NCT06365541
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral Dapagliflozin tablets 10mg/day for 6 months
Trial: NCT05348733
Drug: Kerendia (Finerenone, BAY94-8862)
RxNorm normalized name: Kerendia
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Decision will taken by the treating physician to initiate treatment with finerenone.
Trial: NCT04585789
Drug: JNJ-73763989
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-73763989 will be administered subcutaneously once every 4 weeks up to Week 44.
Trial: NCT06543043
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06543043
Drug: sonrotoclax
RxNorm normalized name: Sonrotoclax
DrugBank: Sonrotoclax (DB18753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06424834
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine taken once orally daily at a starting dose of 2.5mg, uptitrated to a maximum of 10mg if tolerated.
Trial: NCT06424834
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebivolol taken once orally daily at a starting dose of 5mg, uptitrated to a maximum of 20mg if tolerated.
Trial: NCT05652283
Drug: Pamiparib
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamiparib capsule 40 mg/time, twice a day, oral, 3 weeks as a cycle, 3 cycles
Trial: NCT05652283
Drug: Surufatinib
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib 250 mg/time, once a day, oral, 3 weeks as a cycle, 2 cycles
Trial: NCT04585789
Drug: JNJ-56136379
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
Trial: NCT04585789
Drug: Entecavir (ETV)
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
Trial: NCT04585789
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil will be administered orally once daily up to 48 weeks as NA treatment.
Trial: NCT04585789
Drug: Tenofovir alafenamide (TAF)
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TAF will be administered orally once daily up to 48 weeks as NA treatment.
Trial: NCT04585789
Drug: PegIFN-alpha-2a (Optional)
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFN-alpha-2a injection will be administered subcutaneously once weekly after Week 40 for either 12 or 24 weeks.
Trial: NCT04991935
Drug: CC-93538
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-93538